It’s been about a year since the hospital in Fort Scott, Kan., closed. The lessons for this community about meeting its residents’ health needs could provide insights for the rest of the country.
State regulators and even one medevac company have raised doubts about prepaid subscriptions and promised benefits offered by air ambulance companies.
The loss of the longtime hospital in Fort Scott, Kan., forces trauma patients to deal with changing services and expectations.
As the rural town of Fort Scott, Kan., grapples with the closure of its hospital, cancer patients face new challenges as they try to continue their treatments in different locations.
A proposed adjustment to the wage index, used in setting a hospital’s Medicare reimbursement payments, could be a lifeline for some rural facilities.
After depending on the local hospital for more than a century, Fort Scott residents now are trying to cope with life without it.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
Drug pricing is a top issue in the run-up to the midterm elections.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
Research is just beginning on infants born with neonatal abstinence syndrome, and doctors are optimistic that normal development is possible. Monitoring the families and making sure parents are treated for addiction is key.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.